Safety and Efficacy of Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients (Aged 18-59) With Acute Myeloid Leukemia
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 19 Nov 2019 Planned number of patients changed from 30 to 36.
- 29 Nov 2018 Status changed from not yet recruiting to recruiting.
- 13 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Jan 2019.